Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer also advanced its oncology clinical pipeline with several candidates entering late-stage ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

a firm specialising in injectable drugs and biosimilars, at a time when copycat biologics were starting to make real waves in the market. The deal seemed to be a precursor to Pfizer's plans to ...

In fact, the success of biosimilars in Europe has given the United ... UnitedHealthcare announced preferred formulary status for Pfizer’s Retacrit, Amgen’s Mvasi, and Amgen’s Kanjinti.

As global awareness of gender-specific medicine continues to rise, the women's health therapeutics market is entering a pivotal era of innovation and investment. Leading pharmaceutical players—such as ...

The report runs an in-depth analysis of market trends, key players, and future opportunities. The generic drugs market comprises a range of drugs use ...

Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have ...

"BCC Research presents an in-depth analysis of how innovations, market dynamics, regional trends and ESG strategies are shaping the $81.2 billion women's health therapeutics market." BOSTON ...

If President Donald Trump imposes drug tariffs that affect the cheap generic medicines Teva Pharmaceutical Industries makes, ...

Chief Human Resources Officer of Organon & Co. (NYSE:OGN) purchased 5,500 shares, increasing ownership to 62,974 shares.